Login to Your Account



In The Clinic NEWS

Cara Therapeutics Inc.'s opioid candidate CR845 passed with flying colors a critical test, demonstrating significantly lower abuse potential compared to a comparator schedule IV narcotic, results that could give it an edge in the multibillion-dollar analgesic market as the first opioid with a schedule V – perhaps even nonscheduled – labeling.

Celator Pharmaceuticals Inc., which advanced lead compound CPX-351 into a pivotal phase III study in acute myeloid leukemia (AML), hit its target enrollment of 300 patients ahead of schedule and said it would allow others who started the referral and evaluation process to complete enrollment.

Making good on preclinical whispers heard at last year's American Association for the Study of Liver Diseases meeting, Regulus Therapeutics Inc. disclosed interim phase I proof-of-concept data showing that one subcutaneous 2 mg/kg dose of its HCV candidate RG-101 knocked down HCV RNA in a diverse group of patients.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: